Please join us for this educational webinar, where we will discuss current challenges and unmet needs for people with Type 2 diabetes who are advancing treatment to a first injectable and the rationale for choosing a fixed-ratio combination therapy. As part of this dynamic session, we will also highlight data from the recent Soli-D trial, and its potential implications on clinical practice.
Francesco Giorgino
(Chair)
University of Bari,
University Hospital
Policlinico Consorziale,
Bari, Italy
Alice Cheng
Trillium Health Partners,
Unity Health Partners,
University of Toronto,
Toronto, Canada
Linong Ji
Peking University,
Peking University
Diabetes Center,
Beijng, China
Rory McCrimmon
University of Dundee,
NHS Research Scotland,
Dundee, UK
AGENDA
| Timing: 17:00 - 18:00 | Session | Faculty |
| 2 minutes | Welcome and introduction | Francesco Giorgino (Chair) |
| 15 minutes | Current challenges and unmet needs when advancing therapy for adults with T2D | Alice Cheng |
| 15 minutes | Advancing therapy in the Soli-D trial: Comparing iGlarLixi to IDegAsp | Linong Ji |
| 15 minutes | The place of FRC's in clinical practice: What do the data tell us? | Rory McCrimmon |
| 10 minutes | Frequently asked questions: Roundtable discussion | All Speakers |
| 3 minutes | Summary and closing remarks | Francesco Giorgino |
REGISTRATION
To secure your place at the upcoming webinar, please follow the two-step process outlined below:
Step 1: Platform registration
Register for the Sanofi Diabetes webinar series event platform via the ‘REGISTER NOW’ button below.
Step 2: Registration confirmation
Once you have submitted your registration, you will receive a confirmation email containing further instructions on how to secure your place at the webinar.
We look forward to seeing you on Wednesday 27th November!
MAT-GLB-2407125- 1.0 – 10/2024